Continuity of prescribers of short-acting beta agonists among children with asthma

J Pediatr. 2009 Dec;155(6):788-94. doi: 10.1016/j.jpeds.2009.06.033. Epub 2009 Aug 14.

Abstract

Objective: To determine whether short-acting beta-agonist (SABA) prescriber continuity was associated with emergency department visits among children with asthma.

Study design: An analysis of Michigan Medicaid administrative claims (2004-2005) for children ages 5 to 18 with asthma. Logistic regression models assessed the effect of SABA prescriber continuity (the number and site of prescribers) on emergency department visits, controlling for demographics, historical (2004) asthma use and SABA prescription frequency (2-5 low; > or = 6 high).

Results: Most children had one SABA prescriber (62%); 13% had multiple prescribers in the same practice as the primary care provider and 25% had multiple prescribers in different practices. Children with multiple prescribers in different practices had increased odds of an emergency department visit compared with those with 1 prescriber, among those with high SABA prescription frequency (AOR: 2.7, 95% CI: 1.9, 3.9), as well as those with low prescription frequency (AOR: 1.7, 95% CI: 1.3, 2.2).

Conclusions: Children with discontinuity of SABA prescribers have an increased risk of asthma emergency department visits, irrespective of their SABA prescription frequency. Primary care providers may have difficulty identifying patients at high risk with asthma solely on the basis of SABAs prescribed within their own practices.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenergic beta-Agonists / administration & dosage*
  • Asthma / drug therapy*
  • Child
  • Child, Preschool
  • Continuity of Patient Care*
  • Cross-Sectional Studies
  • Drug Prescriptions / statistics & numerical data
  • Emergency Service, Hospital / statistics & numerical data*
  • Female
  • Humans
  • Logistic Models
  • Male
  • Michigan
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Retrospective Studies
  • Risk Factors

Substances

  • Adrenergic beta-Agonists